Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/22/2902587/29517/en/INHALE-3-Study-Reveals-Positive-Readout-in-Head-to-Head-Comparison-of-Inhaled-Insulin-vs-Usual-Care-in-T1D-New-Data-Presented-at-American-Diabetes-Association-s-84th-Scientific-Ses.html
https://www.globenewswire.com/news-release/2024/06/05/2893712/29517/en/Inhale-3-Study-Results-to-be-Presented-During-a-90-Minute-Symposium-on-Saturday-June-22-at-the-American-Diabetes-Association-s-84th-Scientific-Sessions.html
https://www.globenewswire.com/news-release/2024/05/29/2889891/29517/en/MannKind-to-Establish-Boston-Area-Research-Development-Foothold-and-Expand-Portfolio-of-Dry-Powder-Inhalation-Technology-in-Transaction-With-Pulmatrix.html
https://www.globenewswire.com/news-release/2024/05/08/2878285/29517/en/MannKind-Corporation-Reports-2024-First-Quarter-Financial-Results-Provides-Clinical-Development-Update.html
https://www.globenewswire.com/news-release/2024/05/06/2875645/29517/en/MannKind-Receives-U-S-FDA-Fast-Track-Designation-for-Clofazimine-Inhalation-Suspension-for-the-Treatment-of-Nontuberculous-Mycobacterial-NTM-Lung-Disease.html
https://www.globenewswire.com/news-release/2024/05/01/2873589/29517/en/MannKind-Corporation-to-Hold-2024-First-Quarter-Financial-Results-Conference-Call-on-May-8-2024.html
https://www.globenewswire.com/news-release/2024/04/30/2871996/29517/en/MannKind-to-Proceed-With-Phase-1-Nintedanib-Dpi-Mnkd-201-Study-for-Pulmonary-Fibrotic-Diseases.html
https://www.globenewswire.com/news-release/2024/04/29/2871043/29517/en/MannKind-Announces-IND-Clearance-From-U-S-FDA-to-Start-Phase-3-Study-of-Clofazimine-Inhalation-Suspension-for-Nontuberculous-Mycobacterial-NTM-Lung-Disease.html
https://www.globenewswire.com/news-release/2024/04/03/2856718/29517/en/MannKind-Repays-Certain-Debt-Obligations.html
https://www.globenewswire.com/news-release/2024/03/26/2852734/29517/en/MannKind-Announces-CFO-Transition.html